Skip to main content
Fig. 7 | Journal of Hematology & Oncology

Fig. 7

From: Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response

Fig. 7

The effects of corticosteroids on BsAb directed T cell immunotherapy. A Neuroblastoma PDX bearing mice were treated by GD2-BsAb armed T cells (GD2-EATs) with increasing doses of dexamethasone. Dexamethasone was given 1 h before each GD2-EATs or unarmed T cells injection B Peripheral blood (PB) was analyzed by CBC and compared among groups. C Tumors harvested on day 25 were analyzed by flow cytometry (Additional file 1: Fig. S11), and the frequencies of each tumor infiltrating leukocytes were compared among groups. D Immunohistochemical (IHC) staining of tumor sections by anti-human CD3 antibody (× 20) on day 25 after the start of treatment. CD3+ T cell numbers were compared by Q-path analysis. G1, no treatment; G2, unarmed T cells; G3, unarmed T cells plus high-dose (HD) dexamethasone; G4, GD2-EATs; G5, GD2-EATs plus low-dose (LD) dexamethasone; G6, GD2-EATs plus intermediate-dose (ID) dexamethasone; G7, GD2-EATs plus high-dose (HD) dexamethasone. E In vivo anti-tumor response by GD2-EATs with increasing doses of dexamethasone was tested against neuroblastoma PDXs, and long-term survival was compared among groups

Back to article page